Alzamend Neuro | 10-Q: FY2026 Q2 Revenue: USD 0

BUZZ-Alzamend rises after completing mid-stage brain lithium study

Shares of clinical-stage drug developer Alzamend Neurorise 5.74% to $2.58 premarketCo says it finished the clinical portion of a mid-stage trial of AL001, a lithium-based therapy for Alzheimer’s and mood disordersStudy compared AL001 with marketed lithium carbonate to measure lithium levels in blood and brain using advanced imaging, co saysCo says goal is to deliver lithium more effectively to the brain while reducing systemic side effects and avoiding frequent blood testsALZN expects to release the main results in early 2026Up to last close, stock down ~77% YTD

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital | ALZN Stock News

Alzamend Neuro announced the completion of the clinical portion of its Phase II trial for AL001, a novel lithium-delivery system, at Massachusetts General Hospital. The study aims to improve lithium delivery to the brain, reducing systemic side effects. Topline data is expected in Q1 2026. AL001 could transform treatment for Alzheimer's, BD, MDD, and PTSD by eliminating the need for therapeutic drug monitoring. The trial's success marks a significant milestone in developing safer, more effective lithium therapies.

Alzamend Neuro Director Lynne Fahey McGrath Reports Sale of Common Shares

Lynne Fahey McGrath, Director at Alzamend Neuro Inc., has reported the sale of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published by Alzamend Neuro Inc. via EDGAR on October 24, 2025.

Alzamend Neuro Inc Issues 361743 Shares of Common Stock Upon Conversion of Series B Preferred

Alzamend Neuro Inc. issued 361,743 shares of common stock from October 1 to October 8, 2025, following the conversion of approximately 839.2 shares of Series B Convertible Preferred Stock. This issuance was made under an exemption from registration requirements per Section 4(a)(2) of the Securities Act. As of October 8, 2025, the company had 3,801,604 shares of common stock outstanding. The price per share was not disclosed.